Product Description
Bronopol, or 2-Bromo-2-nitro-1,3-propanediol, is an organic compound with wide-spectrum antimicrobial properties. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Bronopol)
Mechanisms of Action: Free Radical Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: France | Germany | Netherlands | Norway | Poland | Spain | Sweden | Taiwan
Approved Indications: None
Known Adverse Events: None
Company: Allerderm
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Dermatitis, Contact|Dermatitis, Allergic Contact
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
Dose Response Trial | P2 |
Active, not recruiting |
Dermatitis, Allergic Contact|Dermatitis, Contact |
2009-11-28 |
|
Safety and Efficacy Trial | P3 |
Active, not recruiting |
Dermatitis, Contact|Dermatitis, Allergic Contact |
2009-03-10 |